Exchange: NASDAQ·Updated 07:30 PM EST

About ACRV

About

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
76

Frequently Asked Questions

Advertisement|Remove ads.